Efficacy and safety of the dual SGLT1 and 2 inhibitor sotagliflozin in combination with a mineralocorticoid receptor antagonist in patients hospitalized for worsening heart failure

被引：0
|
作者：
Pitt, B. [1 ]
Bhatt, D. L. [2 ]
Szarek, M. [3 ]
Davies, M. [4 ]
Banks, P. [4 ]
Steg, P. G. [5 ]
机构：
[1] Univ Michigan, Ann Arbor, MI USA
[2] Icahn Sch Med Mt Sinai, New York, NY USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Lexicon Pharmaceut Inc, The Woodlands, TX USA
[5] Univ Paris Diderot, Bichat Hosp, INSERM, FACT French Alliance Cardiovasc T,UMR1148, Paris, France
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：192 / 193
页数：2
相关论文
共 50 条
  • [1] Sotagliflozin, A Dual SGLT1 And SGLT2 Inhibitor, Reduces First And Subsequent Heart Failure-related Events In Patients Admitted For Worsening Heart Failure
    Pitt, Bertram
    Szarek, Michael
    Banks, Phillip
    Sun, Franklin
    Davies, Michael
    Bhatt, Deepak
    JOURNAL OF CARDIAC FAILURE, 2023, 29 (04) : 683 - 684
  • [2] A Review of the Potential Role of Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor-in the Treatment of Heart Failure
    Tran, Bao Anh C.
    White, Raechel T.
    Bullers, Krystal
    Cornelio, Cyrille K.
    JOURNAL OF PHARMACY TECHNOLOGY, 2024, 40 (05) : 248 - 256
  • [3] The Effect of the Dual SGLT1 and 2 Inhibitor Sotagliflozin on Cardiovascular Mortality and Hospital Readmission Rates for Heart Failure at 30 and 90 Days Post Discharge in Patients With Type 2 Diabetes Hospitalized for Worsening Heart Failure in the SOLOIST-WHF Trial
    Pitt, Bertram
    Bhatt, Deepak L.
    Szarek, Michael
    Sun, Franklin
    Davies, Michael J.
    Steg, Philippe G.
    CIRCULATION, 2022, 146
  • [4] Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?
    Milton Packer
    Nature Cardiovascular Research, 2023, 2 : 705 - 707
  • [5] Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?
    Packer, Milton
    NATURE CARDIOVASCULAR RESEARCH, 2023, 2 (08): : 705 - 707
  • [6] Effect of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, on Systolic Blood Pressure in Patients with Type 2 Diabetes
    Hardin, Marquette
    Davies, Michael
    Carroll, Amy
    Umpierrez, Guillermo
    CIRCULATION, 2024, 150
  • [7] Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
    Sands, Arthur T.
    Zambrowicz, Brian P.
    Rosenstock, Julio
    Lapuerta, Pablo
    Bode, Bruce W.
    Garg, Satish K.
    Buse, John B.
    Banks, Phillip
    Heptulla, Rubina
    Rendell, Marc
    Cefalu, William T.
    Strumph, Paul
    DIABETES CARE, 2015, 38 (07) : 1181 - 1188
  • [8] 24-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem2)
    Danne, Thomas
    Cariou, Bertrand
    Banks, Phillip
    Sawhney, Sangeeta
    Strumph, Paul
    DIABETES, 2017, 66 : LB38 - LB39
  • [9] Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study)
    Bode, B.
    Banks, P.
    Sawhney, S.
    Strumph, P.
    DIABETOLOGIA, 2017, 60 : S87 - S88
  • [10] 24-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem2)
    Danne, T.
    Cariou, B.
    Banks, P.
    Sawhney, S.
    Strumph, P.
    DIABETOLOGIA, 2017, 60 : S87 - S87
12345